Treating Musculoskeletal Pain: The Role of Platelet-Rich Plasma Injections and Stem Cell Therapy

01/29/19 • 21 min

Guest: Jacob L. Sellon, M.D. (@jlsellon)

Host: Darryl S. Chutka, M.D. (@ChutkaMD)

Dr. Jacob Sellon discusses advances in treatment of musculoskeletal pain and osteoarthritis, covering common questions about platelet-rich plasma and stem cell injections. Do they work? What’s the efficacy demonstrated in literature so far? What are the benefits and risks we need to discuss with our patients? What is FDA compliant versus FDA approved treatment and how does this influence insurance coverage and care management? Where does regenerative medicine research need to go?

Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

Guest: Jacob L. Sellon, M.D. (@jlsellon)

Host: Darryl S. Chutka, M.D. (@ChutkaMD)

Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

Previous Episode

Provider and Patient Bias: What Do We Do About Culture's Thumbprint in Medicine?

Guest: Sharonne N. Hayes, M.D. (@SharonneHayes)

Host: Darryl S. Chutka, M.D. (@ChutkaMD)

Dr. Sharonne Hayes discusses the impact of unconscious bias in medicine and how providers can take steps to acknowledge, address, and mitigate these cultural imprints on our automatic thought processes. She then turns the tables discussing patient bias and how health systems and providers can protect and support staff who have been harassed, along with processes that can be put in place to systematically address existing practices that fosters bias.

Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

Deeper Dive:

Project implicit can be found at: https://implicit.harvard.edu/implicit/takeatest.html

Next Episode

Prostate-Specific Antigen (PSA) Testing: A Urologist's Perspective

Guest: Mitchell R. Humphreys, M.D. (@MayoMitch)

Host: Darryl S. Chutka, M.D. (@ChutkaMD)

Prostate cancer is a very common malignancy in men, second only to skin cancer. Despite the fact that it’s one of the more treatable malignancies, it remains the 2nd leading cause of cancer death in men. When diagnosed early, it has an excellent prognosis. The 5-year survival rate approaches 100% in those with local or regional disease. Although screening for prostate cancer is available, the use of screening tests has been controversial and recommendations regarding its use, confusing. Listen in to get a urologist’s perspective.

Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.